Drug Discovery
Drug Discovery covers where GLP-1 came from and where it’s going. Single-agonist (semaglutide), dual-agonist (tirzepatide), triple-agonist (retatrutide in trials), and oral small-molecule (orforglipron, just approved as Foundayo) — each represents a different bet on maximizing efficacy while managing side effects. We explain mechanisms and track the late-stage pipeline.
Do GLP-1 Drugs Cause Cancer? Honest Answer.
A boxed warning, scary headlines, anxious social-media posts. The real cancer evidence on GLP-1 drugs is more nuanced — and…
Latest in Drug Discovery
GLP-1 in 2026: 5 Big Changes Coming Soon
A new pill, a far more powerful drug in trials, a Medicare pilot, a tightening line on compounding. The GLP-1…
Compounded Semaglutide from $147/month
More from Drug Discovery
Compounded Semaglutide: Still Legal in 2026?
Editorial note: This article is a news update covering FDA regulatory action as of May…
GLP-1 Savings & TrumpRx (2026): The $499 Hack
Affiliate disclosure: This article contains affiliate links. We may earn commission when you purchase through…
Mounjaro Cost (2026): Why It’s Pricier Than Zepbound
Affiliate disclosure: This article contains affiliate links. We may earn commission when you purchase through…
Zepbound Cost (2026): Less Than You Think?
Affiliate disclosure: This article contains affiliate links. We may earn commission when you purchase through…
Wegovy Without Insurance: How to Cut the Cost
Affiliate disclosure: This article contains affiliate links. We may earn commission when you purchase through…